Når simvastatin og fenofibrat gives samtidig, er der ikke tegn på, at risikoen for myopati overstiger summen af risici for de enkelte stoffer.
When simvastatin and fenofibrate are given concomitantly, there is no evidence that the risk of myopathy exceeds the sum of the individual risks of each agent.